New ASPS Trial: APROMISS – A Phase III Trial of Anlotinib for Patients with Alveolar Soft Part Sarcoma and Other Sarcomas
OPEN NOW: APROMISS – A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Sponsored by: Advenchen Laboratories, LLC. ClinicalTrials.gov Identifier: NCT03016819 Anlotinib (AL3818), a tyrosine kinase inhibitor, is an investigational drug being evaluated in the treatment of Alveolar Soft Part Sarcoma […]